Novo Nordisk's 13,000 Job Cuts and the Long Wait for a Patent Cliff Cure

Novo Nordisk shares have dropped 24% this year after a 2026-2030 growth reset, with CEO Mike Doustdar betting on CagriSema to rebuild confidence.

Investors are being asked to fund a decade-long transition on faith, and the receipts won't arrive for years.

That is the uncomfortable bargain at the heart of Novo Nordisk's current predicament. Chief executive Mike Doustdar, addressing the fallout from the company's London capital markets day, conceded that confidence must be rebuilt "quarter by quarter" through financial and scientific results rather than rhetoric. The market, for now, is not buying it.

The Danish drugmaker's shares finished Wednesday at EUR 33.66, down 2.2% on the day, extending a seven-day decline to 10%. By Thursday morning the stock was virtually flat in pre-market trade at EUR 33.75. Since the start of the year, the erosion amounts to 24%, leaving the equity well below its former highs.

A Guidance Reset That Landed Badly

The trigger for the selloff was Monday's presentation of plans for 2026 through 2030. Novo is targeting revenue growth merely in line with the broader pharmaceutical industry — a sharp deceleration from the rates investors had grown accustomed to. The stock fell 8% immediately after the event.

Citi analysts expect annual growth in the mid-single digits through 2030 and kept their rating at "Neutral." Jefferies flagged that the company's portfolio remains heavily concentrated in obesity. Layered on top is the looming expiry of key semaglutide patents in leading markets in the early 2030s, a cliff edge that gives the market plenty to worry about.

Doustdar's response has been to cut deep. Roughly 13,000 employees left the group over the past twelve months, the company confirmed — a figure that includes the 9,000 job reductions previously announced plus another 4,000 departures.

CagriSema Carries the Weight

The bull case rests largely on the next generation of obesity therapies. Novo plans to launch its combination drug CagriSema in early 2027. In clinical trials, the candidate produced average weight loss of 21% after 16 months in people with obesity. In a separate study of adults with type 2 diabetes, CagriSema achieved 12.4% average weight loss, against 9.1% for Eli Lilly's tirzepatide, while matching its rival on HbA1c reduction. Among overweight or obese adults, CagriSema delivered 21.0% weight loss versus just 2.0% for placebo.

Manufacturing scale is the next battleground. Novo intends to expand global production capacity for obesity pills tenfold by 2030. Doustdar is preparing for a scenario in which tablets capture as much as half the global market for obesity treatments by the end of the decade. For its already-approved Wegovy pill, the company reported revenue of just under DKK 5.5 billion for the first half of 2026, with delivery-technology patents expected to shield the franchise from generics until the mid- to late 2030s.

Beyond Obesity, and a Possible New York Listing

Novo is also pushing into liver, cardiovascular and blood disorders. Management has dangled more than five potential blockbuster medicines by 2030, with risk-adjusted pipeline revenue of over DKK 150 billion targeted by 2035. Doustdar did not rule out acquisitions to bolster adjacent fields.

On the capital markets front, he told the Financial Times he is open to a direct listing on the New York Stock Exchange, where US investors currently rely mostly on depositary receipts. No active process is underway, however.

The Analyst Pushback

Sell-side sentiment has turned colder. Deutsche Bank trimmed its price target to DKK 245 from DKK 265 while maintaining a sell recommendation. Jefferies, according to media reports, cut its target to DKK 275 from DKK 285 with an unchanged hold rating.

The concern is straightforward: Novo risks ceding pricing power in its core diabetes and obesity markets. Eli Lilly is pressing with competing offerings, and the approaching semaglutide patent expiry threatens margin and price pressure. If copycat drugs arrive faster than the new pipeline generates revenue, current margins are exposed.

The Levels That Matter

Technically, the EUR 30.25 52-week low is the line in the sand. Holding above it leaves room for stabilization, with investors rewarding progress on CagriSema's clinical development and the long-range pipeline ambitions. A sustained break below, however, would risk widening the correction as the market prices in a deeper hit to future earnings.

The next tangible catalyst is likely further progress on CagriSema's regulatory filings. Shareholders must now weigh whether pipeline wins outweigh the very real transition risks stretching to the end of the decade.